Diessner J, Van Ewijk R, Weiss C R, Janni W, Wischnewsky M B, Kreienberg R, Hancke K, Blettner M, Wöckel A, Schwentner L
Department for Obstetrics and Gynecology, University of Würzburg Medical School, Josef-Schneider-Str. 4, 97080, Würzburg, Germany,
Arch Gynecol Obstet. 2015 Sep;292(3):655-64. doi: 10.1007/s00404-015-3691-4. Epub 2015 Mar 27.
Inflammatory breast cancer (IBC) represents a rare and aggressive form of cancer with negative prognosis and high rate of recurrence. The purpose of this retrospective multi-center study was to evaluate the effect of IBC on overall and disease-free survival. Furthermore we analyzed the influence of hormone and Her2 receptor expression on inflammatory breast cancer cells on the clinical outcome of patients.
This retrospective German multi-center study included 11,780 patients with primary breast cancer recruited from 1992 to 2008. In this sub-group analysis we focused on 70 patients with IBC.
Despite the relatively small sample size, we could confirm the aggressiveness of inflammatory breast cancer and the different clinical behavior of IBC subtypes. It could be demonstrated that the lack of expression of hormone receptors on tumor cells is associated with a more aggressive clinical course and decreased overall and disease-free survival. Higher incidence of Her2 overexpression, that is typically associated with poor prognostic outcome among women with non-IBC tumors, seems however to have no prognostic significance.
This BRENDA sub-group analysis, on a German cohort of breast cancer patients confirmed the negative outcome of IBC and the different clinical behavior of IBC subtypes. The best management of IBC requires intensive coordination and cooperation between various clinical disciplines involved in the treatment of IBC patients. Moreover there is a need to identify IBC-specific targeted therapies to improve the curing prospects of this subtype of cancer.
炎性乳腺癌（IBC）是一种罕见且侵袭性强的癌症，预后不良且复发率高。这项回顾性多中心研究的目的是评估IBC对总生存期和无病生存期的影响。此外，我们分析了激素和Her2受体表达对炎性乳腺癌细胞的影响及其对患者临床结局的影响。
这项回顾性德国多中心研究纳入了1992年至2008年招募的11780例原发性乳腺癌患者。在这个亚组分析中，我们聚焦于70例IBC患者。
尽管样本量相对较小，但我们能够证实炎性乳腺癌的侵袭性以及IBC亚型不同的临床行为。结果表明，肿瘤细胞上激素受体表达的缺失与更具侵袭性的临床病程以及总生存期和无病生存期的降低相关。然而，Her2过表达的较高发生率（这在非IBC肿瘤女性中通常与不良预后结果相关）似乎没有预后意义。
这项针对德国乳腺癌患者队列的BRENDA亚组分析证实了IBC的不良结局以及IBC亚型不同的临床行为。IBC的最佳管理需要参与IBC患者治疗的各个临床学科之间进行密切的协调与合作。此外，有必要确定IBC特异性靶向治疗方法，以改善这种癌症亚型的治愈前景。
